cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 3, 2007, Pages 349-360

  Bianchini, Michele ^a   Martinelli, Giovanni ^b   Renzulli, Matteo ^b   Gonzalez Cid, Marcela ^a   Larripa, Irene ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Amifostine; Apoptosis; BTF; Imatinib; Microarray

Indexed keywords

ACTIFOS; AMIFOSTINE; APOPTOSIS INHIBITOR 5; BCL 2 ASSOCIATED TRANSCRIPTION FACTOR; BETA TUBULIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IMATINIB; ISOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN PHOSPHATASE 1E; RNA; TOUSLED LIKE KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; INCUBATION TIME; LEUKEMIA CELL LINE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PHARMACOGENETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING;

AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL SURVIVAL; DNA-BINDING PROTEINS; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; PYRIMIDINES; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 33845900963     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0276-8     Document Type: Article

References (34)

1. Cortes JE, Talpaz M, Kantarjian H (1996) Chronic myelogenous leukemia: a review. Am J Med 100:555-570
2. Laurent E, Talpaz M, Kantarjian H, Kurzrock R (2001) The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 61:2343-2355
3. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164-172
4. Evans C, Owen-Lynch P, Whetton AD, Dive C (1993) Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 53:1735-1738
5. Goldman JM, Melo JV (2003) Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 349:1451-1464
6. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
8. Deininger M, Buchdunger E, Druker BJ (2005a) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640-2653
9. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11):2190-2196
10. Hui CH, Hughes TP (2003) Strategies for the treatment of imatinib-resistant chronic myeloid leukemia. Clin Adv Hematol Oncol 1(9):538-545, 559
11. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070-1079
12. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4(2):75-85
13. 3 enhances selective cytotoxic effects of STI-571 against Brc-Ablpositive acute leukemia cells. Leukemia 5:772-778
14. Kim JS, Jeung HK, Cheong JW, Maeng H, Lee ST, Hahn JS, Ko YW, Min YH (2004) Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br J Haematol 124(2):166-178
15. Deininger M, Buchdunger E, Druker BJ (2005b) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640-2653
16. Vellon L, Gonzalez Cid M, Nebel MD, Larripa I (2005) Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line. Cancer Chemother Pharmacol 55:602-608
17. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275(32):24273-24278
18. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4(10):R70
19. Yang YH, Speed T (2002) Design issues for cDNA microarray experiments. Nat Rev Genet 3:579-588
20. Tichopad A, Dilger M, Schwarz G, Pfaffl MW (2003) Standardized determination of real-time PCR efficiency from a single reaction set-up. Nucleic Acids Res 31(22):6688
21. Grzanka A, Grzanka D, Orlikowska M (2003) Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. Biochem Pharmacol 66(8):1611-1617
22. Ferrando AA, Penda AM, Llano E, Velasco G, Lidereau R, Carlos Lopez-Otin C (1997) Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase. J Biol Chem 272(52):33298-33304
23. McCright B, Virshup DM (1995) Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem 270(44):26123-26128
24. Klumpp S, Krieglstein J (2002) Serine/threonine protein phosphatases in apoptosis. Curr Opin Pharmacol 2(4):458-462
25. Saydam G, Aydin HH, Sahin F, Selvi N, Oktem G, Terzioglu E, Buyukkececi F, Omay SB (2003) Involvement of protein phosphatase 2A in interferon-alpha-2b- induced apoptosis in K562 human chronic myelogenous leukaemia cells. Leuk Res 27(8):709-717
26. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8:355-368
27. Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P (1998) A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. J Cell Biol 141:187-197
28. Kasof GM, Goyal L, White E (1999) Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol 19:4390-4404
29. Fritz G, Kaina B (1001) Ras-related GTPase RhoB represses NF-kB signaling. J Biol Chem 276:3115-3122
30. Esteve P, Embade N, Perona R, Jimenez B, del Peso L, Leon J, Arends M, Miki T, Lacal JC (1998) Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway. Oncogene 17:1855-1869
31. Embade N, Valeron PF, Aznar S, Lopez-Collazo E, Juan Carlos Lacal (2000) Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production. Mol Biol Cell 11:4347-4358
32. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW (2003) High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 101(6):2152-2155
33. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ (2002) In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30(7):729-737
34. Tarumoto T, Nagai T, Ohmine K, Miyoshi T, Nakamura M, Kondo T, Mitsugi K, Nakano S, Muroi K, Komatsu N, Ozawa K (2004) Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp Hematol 32(4):375-381